Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share...
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price targe...
TD Cowen analyst Dan Brennan maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $8 to $9.
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from $6 to $8.
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs $0.01 analyst estimate. Af...
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst consensus estimate of $204.89...
